

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

HYBRIGENICS SA,
Petitioner,

v.

FORMA THERAPEUTICS, INC.
Patent Owner

PGR2018-00098
Patent 9,840,491

DECLARATION OF STEPHANIE L. SCHONEWALD, PHD, JD

I, Stephanie L. Schonewald, hereby declare as follows:

1. EX2012 is a true and correct copy of a January 26, 2015 Press Release, entitled “Hybrigenics extends its partnership with Servier in the field of Ubiquitin-Specific Proteases inhibitors,” which I downloaded from <https://www.hybrigenics.com/news/articles/list/p/5/type/2> on June 10, 2019.
2. EX2013 is a true and correct copy of an October 10, 2016 Press Release, entitled “Hybrigenics and Servier reach a new step in their R&D partnership,” which I downloaded from <https://www.hybrigenics.com/news/articles/list/p/3/type/2> on June 10, 2019.
3. EX2014 is a true and correct copy of a September 26, 2013 Press Release, entitled “Hybrigenics incorporates an American subsidiary,” which I downloaded from <https://www.hybrigenics.com/news/articles/list/p/8/type/2> on June 10, 2019.
4. EX2015 is a true and correct copy of a May 18, 2017 Press Release, entitled “Hybrigenics’ inhibitor of Ubiquitin-Specific Protease 7 (USP7) shows activity in preclinical models of Chronic Lymphocytic Leukemia (CLL),” which I downloaded from <https://www.hybrigenics.com/news/articles/list/p/2/type/2> on June 10, 2019.
5. EX2016 is a true and correct copy of a February 13-14, 2017 Slide Deck, entitled “Bio-CEO & Investor, New York,” which I downloaded from

- https://www.hybrigenics.com/files/news/articles/Publications/bio-ceo_new_york_feb_13-14_2017_on_line.pdf on June 10, 2019.
6. EX2017 is a true and correct copy of a January 20, 2016 Slide Deck, entitled “Corporate presentation,” which I downloaded from https://abid.co/sites/default/files/hybrigenics_corporate_presentation_2016_january_20.pdf on June 10, 2019.
 7. EX2018 is a true and correct copy of a September 20, 2016 Slide Deck, entitled “Corporate presentation,” which I downloaded from http://www.hybrigenics.com/files/news/articles/Publications/hybrigenics_corporate_presentation_2016_september_20.pdf on June 10, 2019.
 8. EX2019 is a true and correct copy of a June 14, 2017 Report from Arrowhead, entitled “Diligence and Valuation Report,” which I downloaded from https://www.hybrigenics.com/files/news/articles/arrowhead_report_hybrigenics_14_june_2017.pdf on June 10, 2019.
 9. EX2020 is a true and correct copy of a June 2016 Report, entitled “Hybrigenics, A new standard of care for AML,” which I downloaded from https://www.hybrigenics.com/files/news/articles/Publications/gilbert_dupont_hybrigenics_june_2016.pdf on June 10, 2019.

I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code.

Respectfully submitted,

Date: June 11, 2019

By: 

Stephanie L. Schonewald, Reg. No. 72,452
CHOATE HALL & STEWART LLP
Two International Place
Boston, MA 02110
617-248-5000

CERTIFICATE OF SERVICE

I hereby certify that on June 12, 2019, I caused a true and correct copy of the
DECLARATION OF STEPHANIE L. SCHONEWALD, PHD, JD to be served
via electronic mail on the following attorneys of record:

- alexipdock@stites.com

Date: June 12, 2019 By: /John P. Rearick/

John P. Rearick (Reg. No. 64,909)
Stephanie L. Schonewald (Reg. No. 72,452)
Brenda Herschbach Jarrell (Reg. No. 39,223)
Sophie F. Wang (*pro hac vice motion* to be filed)
Michael A. Shinall (Reg. No. 72,676)
Nicholas J. Pace (Reg. No. 74, 316)
CHOATE, HALL & STEWART LLP
Two International Place
Boston, MA 02110
Tel: (617) 248-5000

Nicholas Boivin (Reg. No. 45,650)
FORMA Therapeutics, Inc.
500 Arsenal Street
Watertown, MA 02472
857-209-2495

Attorneys/Agents for Petitioner